Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers

Yuanfang Li,Baiwei Zhao,Juzheng Peng,Hailin Tang,Sicheng Wang,Sicheng Peng,Feng Ye,Junye Wang,Kai Ouyang,Jianjun Li,Manbo Cai,Yongming Chen
DOI: https://doi.org/10.1016/j.drup.2023.101042
IF: 22.841
2024-01-15
Drug Resistance Updates
Abstract:Drug resistance in cancer remains a major challenge in oncology, impeding the effectiveness of various treatment modalities. The nuclear factor-kappa B (NF-κB) signaling pathway has emerged as a critical player in the development of drug resistance in cancer cells. This comprehensive review explores the intricate relationship between NF-κB and drug resistance in cancer. We delve into the molecular mechanisms through which NF-κB activation contributes to resistance against chemotherapeutic agents, targeted therapies, and immunotherapies. Additionally, we discuss potential strategies to overcome this resistance by targeting NF-κB signaling, such as small molecule inhibitors and combination therapies. Understanding the multifaceted interactions between NF-κB and drug resistance is crucial for the development of more effective cancer treatment strategies. By dissecting the complex signaling network of NF-κB, we hope to shed light on novel therapeutic approaches that can enhance treatment outcomes, ultimately improving the prognosis for cancer patients. This review aims to provide a comprehensive overview of the current state of knowledge on NF-κB and its role in drug resistance, offering insights that may guide future research and therapeutic interventions in the fight against cancer.
pharmacology & pharmacy
What problem does this paper attempt to address?